PMV Pharmaceuticals (PMVP) Capital Expenditures (2020 - 2025)
PMV Pharmaceuticals' (PMVP) quarterly Capital Expenditures came in at $15000.0 in Q4 2025, down 73.21% YoY from $56000.0 in Q4 2024, and up 1600.0% on a QoQ basis from -$1000.0 in Q3 2025.
PMV Pharmaceuticals (PMVP) Capital Expenditures (2020 - 2025) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 6 years of Capital Expenditures data on file, last reported at $15000.0 in Q4 2025.
- Quarterly Capital Expenditures fell 73.21% year-over-year to $15000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $25000.0 (down 61.54% YoY) and the FY2025 annual result came in at $29000.0, down 95.57% from the prior year.
- Capital Expenditures rose to $15000.0 in Q4 2025, from -$1000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $4.8 million in Q3 2022 to a low of -$6.1 million in Q4 2022.
- A 5-year average of $111750.0 and a median of $88000.0 in 2021 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2021 — Capital Expenditures surged 1152.5% — and 2022, when it plunged 2447.33%.
- Tracing PMVP's Capital Expenditures over 5 years: stood at $262000.0 in 2021, then sank by 2447.33% to -$6.1 million in 2022, then jumped by 87.66% to -$759000.0 in 2023, then surged by 107.38% to $56000.0 in 2024, then slumped by 73.21% to $15000.0 in 2025.
- The last three Capital Expenditures figures came in at $15000.0 (Q4 2025), -$1000.0 (Q3 2025), and $11000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 251.02 Mn |
| 10 | PMV Pharmaceuticals | 69.94 Mn | -9.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 56,000.00 |
| Dec 31, 2024 | 56,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 594,000.00 |
| Mar 31, 2024 | 594,000.00 |
| Dec 31, 2023 | -759,000.00 |
| Dec 31, 2023 | -759,000.00 |
| Sep 30, 2023 | 44,000.00 |
| Sep 30, 2023 | 44,000.00 |